Pluserix Glaxo
SmithKline & Immravax Aventis Pasteur MSD Ltd
(aka Urabe)
[back] MMR vaccines
[Canada withdrew licences for the vaccine in May 1990.
Two years later, on
September 14, 1992 two measles vaccines (Pluserix & Immravax) were
banned in the UK after it was revealed that children had developed meningitis.
On
Sept 16, 1992 the New Zealand government withdrew Pluserix. Five
years later in 1997:
the Smith Kline Beecham Urabe MMR jab was used in a mass vaccination programme
in Brazil. Just one example of the complete disregard for child health
from vaccine companies and Pharma shills such as the UK Government.
The men involved on the vaccine committee that approved
Pluserix included
Salisbury, Professor McDevitt,
DAVID HULL &
Professor George Nuki, all connected to the
persecution of Dr Wakefield. See:
[pdf 8 March 1988]]
See Genocide in Africa via Oral Polio Vaccine
See: "Pichichero has served as consultant to the World Health Organization, and his research has held considerable weight in the WHO decision to continue using thimerosal in vaccines administered in nations outside the United States."--- [Jan 2008] Babies excrete vaccine-mercury quicker than originally thought
[2009 April] FARNINGHAM: Mum attends autistic rally Mrs Butler’s 19-year-old son, Matthew, was diagnosed with the condition when he was just 18 months old. Matthew developed autism after having an MMR jab.
[2009 Jan] Secret British MMR Vaccine Files Forced Open By Legal Action
MMR Urabe and deafness
[March 2007]
PARENTS FIGHT TO PROVE GIRL LEFT DEAF BY MMR
VACCINE
[April 2008] MMR/AUTISM & THE TAMING OF THE BRITISH MEDIA--Clifford Miller
[2007] Parliament was given false MMR assurance
[2007]
Revealed: how Whitehall dismissed MMR alarms
[June 2007 Private Eye] MMR Conflict of Interest Zone
[March 2007] Vaccine officials knew about MMR risks
[March 2007] Early fears about MMR in secret papers Katie Stephen was a healthy baby girl when she was injected with the MMR triple vaccine. Ten days later she was vomiting, delirious and running a fever. That was in 1990. Seventeen years later, she is deaf in one ear.....Toby Stewart of west London was one of the children given it. He soon developed encephalitis-type symptoms and was left with what his father Andy, a business consultant, describes as "low-scale brain damage".
[Media UK, April 2001 MMR] Jab risk was ignored
[Media Aug 2002] Health authorities block import of unlicensed single mumps vaccine
[Media June 2000, MMR--meningitis & death] Mother’s regret over son who still suffers JULIET Parsons still finds it difficult to talk abut the time her son developed meningitis after he was given the Urabe jab nine years ago. She said Matthew continues to suffer side effects. He has learning difficulties, still has fits and regularly gets ill due to a weak immune system.
MMR vaccine & aseptic meningitis, Japan 1989-1993
JOINT COMMITTEE ON VACCINATION AND IMMUNISATION
[See: JCVI]
JOINT
SUB-COMMITTEE ON ADVERSE REACTIONS TO VACCINES AND IMMUNOLOGICAL PRODUCTS
[8 March 1988]
[copy 2]
Salisbury,
McDevitt,
HULL,
Meadow,
Miller,
Rotblat,
[6 Oct 1989]
Salisbury,
Meadow,
Miller
[17 Sept 1990]
Salisbury,
McDevitt
Meadow,
Miller
Citations:
OUTBREAK OF ASEPTIC MENINGITIS
ASSOCIATED WITH MASS VACCINATION WITH A URABE CONTAINING MMR VACCINE
Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo A, Lucena R, Barreto ML.Outbreak
of aseptic meningitis associated with mass vaccination with a urabe-containing
measles-mumps-rubella vaccine: implications for immunization programs. Am J Epidemiol. 2000 Mar 1;151(5):524-30. PMID: 10707922
A mass immunization campaign with a Urabe-containing measles-mumps-rubella
vaccine was carried out in 1997 in the city of Salvador, northeastern Brazil, with a
target population of children aged 1-11 years. There was an outbreak of aseptic meningitis
following the mass campaign. Cases of aseptic meningitis were ascertained through data
collected from the records of children admitted to the local referral hospital for
infectious diseases between March and October of 1997, using previously defined
eligibility criteria. Vaccination histories were obtained through home visits or telephone
calls. Eighty-seven cases fulfilled the study criteria. Of those, 58 cases were diagnosed
after the vaccination campaign. An elevated risk of aseptic meningitis was observed 3
weeks after Brazil's national vaccination day compared with the risk in the prevaccination
period (relative risk = 14.3; 95% confidence interval: 7.9, 25.7). This result was
confirmed by a case series analysis (relative risk = 30.4; 95% confidence interval: 11.5,
80.8). The estimated risk of aseptic meningitis was 1 in 14,000 doses. This study confirms
a link between measles-mumps-rubella vaccination and aseptic meningitis. The authors
discuss the implications of this for the organization and planning of mass immunization
campaigns.
Autret E, Jonville-Bera AP, Galy-Eyraud C, Hessel L.[Aseptic meningitis after mumps vaccination].Therapie. 1996 Nov-Dec;51(6):681-3. French.PMID: 9164005
The aim of this retrospective study was to evaluate the incidence and the characteristics of spontaneously reported aseptic meningitis (AM) in France following mumps vaccination with monovalent or multivalent vaccines containing the Urabe strain. Fifty-four cases of AM were reported to the regional drug surveillance centres or to the manufacturer from the time each vaccine was launched up until June 1992. Twenty cases were associated with the time off administration of a monovalent mumps vaccine and 34 with a trivalent measles, mumps and rubella vaccine (MMR). A mumps virus was isolated in four cases in the cerebrospinal fluid and an Urabe-like strain was characterised twice by polymerase chain reaction (PCR). A probable mumps origin was assumed in 17 other cases where the patients presented with other clinical or biological signs of mumps infection. The clinical outcome of AM was always favourable. The global incidence of mumps vaccine-associated AM was 0.82/100,000 doses, which is significantly lower than the incidence in the unvaccinated population. Even considering that the actual incidence of AM is much higher when assessed by active surveillance studies, the risk/benefit ratio of mumps vaccine remains in favour of vaccination. The incidence of mumps vaccines containing Jeryl Lynn (ROR Vax et Imu ORR) associated with AM needs to be evaluated.
Kimura
M, Kuno-Sakai H, Yamazaki S, Yamada A, Hishiyama M, Kamiya H, Ueda K, Murase T, Hirayama
M, Oya A, Nozaki S, Murata R.Adverse events associated with MMR vaccines
in Japan. Acta Paediatr Jpn. 1996 Jun;38(3):205-11.PMID: 8741307
The largest nationwide active surveillance of four Measles-Mumps-Rubella
(MMR) vaccines was conducted in Japan. A total of 1255 pediatricians actively participated
in the study, which comprised 8.6% of all members of the Japanese Pediatric Society. The
total number of registered recipients of MMR vaccines was 38 203. They were arbitrarily
given one of the MMR vaccines produced by three makers (Takeda, Osaka city, Kitasato
Minato-ku. Tokyo and Biken Suita city, Japan) or the standard MMR vaccine made of
designated strains (Kitasato's measles-AIK-C, Biken's mumps-Urabe Am9 and Takeda's
rubella-To336) produced by Takeda, Kitasato and Biken and were observed for 35 days. The
rates of virologically confirmed aseptic meningitis per 10,000 recipients were 16.6, 11.6,
3.2 and 0 for the standard MMR, Takeda MMR, Kitasato MMR and Biken MMR vaccines,
respectively. The incidence of convulsions between 15 and 35 days was the highest with the
standard MMR vaccine and the incidence of fever associated with vomiting occurring between
15 and 35 days (symptoms relevant to aseptic meningitis) were also the highest with the
standard MMR vaccine. The incidence of parotid swelling was the lowest with Takeda MMR
vaccine. This surveillance revealed that incidences of aseptic meningitis after
administration of the standard MMR vaccine and of Biken MMR vaccine were different. This
posed questions about the manufacturing consistency of the Urabe Am9 mumps virus vaccines.
On the other hand, the National Institute of Health found that the biological
characteristics of the Urabe Am9 mumps virus contained in the standard MMR vaccine and in
the Biken MMR vaccine were different. The Biken Company reported that the mumps vaccine in
the standard MMR vaccine was a mixture of two Urabe Am9 mumps vaccine bulks; one identical
to that contained in the Biken MMR vaccine and the other produced by a different
manufacturing process. PMID: 8741307